Bernd Brust Buys 216,212 Shares of Maravai LifeSciences (NASDAQ:MRVI) Stock

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) CEO Bernd Brust purchased 216,212 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The shares were purchased at an average cost of $3.25 per share, with a total value of $702,689.00. Following the completion of the purchase, the chief executive officer owned 466,771 shares in the company, valued at $1,517,005.75. This trade represents a 86.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Bernd Brust also recently made the following trade(s):

• On Wednesday, November 12th, Bernd Brust acquired 93,358 shares of Maravai LifeSciences stock. The stock was purchased at an average cost of $3.21 per share, for a total transaction of $299,679.18.
• On Tuesday, November 11th, Bernd Brust bought 157,201 shares of Maravai LifeSciences stock. The shares were acquired at an average price of $3.24 per share, with a total value of $509,331.24.

Maravai LifeSciences Trading Up 8.4%

MRVI opened at $3.62 on Wednesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29. The stock’s 50 day moving average price is $3.09 and its 200-day moving average price is $2.62. Maravai LifeSciences Holdings, Inc. has a one year low of $1.66 and a one year high of $6.21. The stock has a market cap of $925.66 million, a price-to-earnings ratio of -4.31 and a beta of 0.34.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The business had revenue of $41.63 million for the quarter, compared to the consensus estimate of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. On average, equities analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Institutional Trading of Maravai LifeSciences

Hedge funds have recently added to or reduced their stakes in the business. Monaco Asset Management SAM increased its holdings in Maravai LifeSciences by 315.0% during the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock valued at $10,494,000 after buying an additional 2,775,372 shares during the period. Philosophy Capital Management LLC bought a new stake in Maravai LifeSciences during the 1st quarter valued at $5,731,000. Tejara Capital Ltd increased its holdings in shares of Maravai LifeSciences by 257.8% in the 2nd quarter. Tejara Capital Ltd now owns 1,941,449 shares of the company’s stock valued at $4,679,000 after acquiring an additional 1,398,900 shares during the period. 12 West Capital Management LP raised its position in shares of Maravai LifeSciences by 8.0% in the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company’s stock worth $27,672,000 after acquiring an additional 930,000 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Maravai LifeSciences by 67.6% during the 1st quarter. Deutsche Bank AG now owns 2,072,239 shares of the company’s stock worth $4,580,000 after purchasing an additional 835,600 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRVI. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Royal Bank Of Canada dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Maravai LifeSciences currently has an average rating of “Hold” and a consensus price target of $5.22.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.